Rapid detection of traditional Chinese medicine with neuraminidase inhibitory activities based on high-throughput and virtual screening strategy

[1]  Jing Chen,et al.  Oseltamivir Treatment for Influenza During the Flu Season of 2018–2019: A Longitudinal Study , 2022, Frontiers in Microbiology.

[2]  Fang Wang,et al.  Screening S protein – ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19 , 2021, European Journal of Medicinal Chemistry.

[3]  Talia B. Kimber,et al.  Deep Learning in Virtual Screening: Recent Applications and Developments , 2021, International journal of molecular sciences.

[4]  Cheng Lu,et al.  Traditional Chinese Medicine in Treating Influenza: From Basic Science to Clinical Applications , 2020, Frontiers in Pharmacology.

[5]  Anthony S. Wexler,et al.  Influenza A virus is transmissible via aerosolized fomites , 2020, Nature Communications.

[6]  Zhi‐Jun Zhang,et al.  Development of anti‐influenza agents from natural products , 2020, Medicinal research reviews.

[7]  Zhengjin Jiang,et al.  Rapid identification and isolation of neuraminidase inhibitors from mockstrawberry (Duchesnea indica Andr.) based on ligand fishing combined with HR-ESI-Q-TOF-MS , 2020, Acta pharmaceutica Sinica. B.

[8]  Ha T. Nguyen,et al.  Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018. , 2020, Antiviral research.

[9]  H. Goossens,et al.  Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial , 2019, The Lancet.

[10]  N. Xia,et al.  Nanobody-based sandwich reporter system for living cell sensing influenza A virus infection , 2019, Scientific Reports.

[11]  M. Bassetti,et al.  Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives , 2019, Expert opinion on pharmacotherapy.

[12]  A. Hurt,et al.  Neuraminidase inhibitor resistance in influenza: a clinical perspective , 2018, Current opinion in infectious diseases.

[13]  Peng Zhan,et al.  Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant. , 2018, Journal of medicinal chemistry.

[14]  T. Clark,et al.  Treatment of influenza with neuraminidase inhibitors , 2018, Current opinion in infectious diseases.

[15]  Peng Zhan,et al.  Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant. , 2018, Journal of medicinal chemistry.

[16]  Jan Kyncl,et al.  Estimates of global seasonal influenza-associated respiratory mortality: a modelling study , 2017, The Lancet.

[17]  Jiabo Wang,et al.  Inhibition activity of a traditional Chinese herbal formula Huang-Lian-Jie-Du-Tang and its major components found in its plasma profile on neuraminidase-1 , 2017, Scientific Reports.

[18]  R. Webby,et al.  Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes , 2017, Journal of Virology.

[19]  K. Subbarao,et al.  Influenza , 2017, The Lancet.

[20]  C. Liao,et al.  Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies , 2017, Infection and drug resistance.

[21]  Nathorn Chaiyakunapruk,et al.  Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics , 2017, British journal of clinical pharmacology.

[22]  Zhenzhong Wang,et al.  Antiviral activity of chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of neuraminidase , 2017, Scientific Reports.

[23]  Yan Liu,et al.  Screening and evaluation of commonly-used anti-influenza Chinese herbal medicines based on anti-neuraminidase activity. , 2016, Chinese journal of natural medicines.

[24]  Dusanka Janezic,et al.  H274Y's Effect on Oseltamivir Resistance: What Happens Before the Drug Enters the Binding Site , 2016, J. Chem. Inf. Model..

[25]  Wei Zhou,et al.  TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.

[26]  Curtis J Henrich,et al.  Matching the power of high throughput screening to the chemical diversity of natural products. , 2013, Natural product reports.

[27]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[28]  C. Ling.  Expression and Application of Neuraminidase of Influenza Virus , 2009 .